Brinker Capital Investments LLC bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,167 shares of the company's stock, valued at approximately $238,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Captrust Financial Advisors lifted its holdings in Turning Point Therapeutics by 176.5% in the first quarter. Captrust Financial Advisors now owns 1,045 shares of the company's stock valued at $28,000 after acquiring an additional 667 shares during the period. US Bancorp DE lifted its holdings in Turning Point Therapeutics by 139.6% in the first quarter. US Bancorp DE now owns 1,143 shares of the company's stock valued at $31,000 after acquiring an additional 666 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Turning Point Therapeutics during the 1st quarter worth $96,000. Syquant Capital Sas acquired a new position in shares of Turning Point Therapeutics during the 2nd quarter worth $339,000. Finally, Stonnington Group LLC acquired a new position in shares of Turning Point Therapeutics during the 2nd quarter worth $383,000. Institutional investors and hedge funds own 90.33% of the company's stock.
Get Turning Point Therapeutics alerts:Turning Point Therapeutics Stock Performance
Turning Point Therapeutics stock opened at $76.01 on Friday. The stock has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. The stock has a 50-day moving average price of $75.81 and a 200 day moving average price of $59.18. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $82.20.
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.48) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by ($0.70). The company had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. The company's quarterly revenue was down 97.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.14) EPS. On average, equities analysts predict that Turning Point Therapeutics, Inc. will post -7.69 EPS for the current year.Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on TPTX shares. Guggenheim set a $76.00 price target on Turning Point Therapeutics in a research note on Monday, June 20th. SVB Leerink downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $78.22.
Insider Buying and Selling at Turning Point Therapeutics
In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of Turning Point Therapeutics stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the completion of the sale, the chief financial officer now owns 28,700 shares in the company, valued at approximately $2,150,778. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.60% of the stock is owned by company insiders.
Turning Point Therapeutics Profile
(Get Rating)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- ConAgra Brands Is A Value Pick For Income Investors
- 3 Stocks With Market-Beating Price Performance
- Lucid Motors May Test Investors' Resolve, But Should They Sell?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.